Role of Bcl2 in Osteoclastogenesis and PTH Anabolic Actions in Bone

Overview

Journal J Bone Miner Res

Publisher Oxford University Press

Date 2007 Dec 19

PMID 18086008

Citations 30

Authors

Junro Yamashita

Nabanita S Datta

Yong-Hee P Chun

Dong-Ye Yang

Allison A Carey

Jaclynn M Kreider

Steven A Goldstein

Laurie K McCauley

Affiliations

Soon will be listed here.

Abstract

Introduction: B-cell leukemia/lymphoma 2 (Bcl2) is a proto-oncogene best known for its ability to suppress cell death. However, the role of Bcl2 in the skeletal system is unknown. Bcl2 has been hypothesized to play an important anti-apoptotic role in osteoblasts during anabolic actions of PTH. Although rational, this has not been validated in vivo; hence, the impact of Bcl2 in bone remains unknown.

Materials And Methods: The bone phenotype of Bcl2 homozygous mutant (Bcl2(-/-)) mice was analyzed with histomorphometry and muCT. Calvarial osteoblasts were isolated and evaluated for their cellular activity. Osteoclastogenesis was induced from bone marrow cells using RANKL and macrophage-colony stimulating factor (M-CSF), and their differentiation was analyzed. PTH(1-34) (50 microg/kg) or vehicle was administered daily to Bcl2(+/+) and Bcl2(-/-) mice (4 days old) for 9 days to clarify the influence of Bcl2 ablation on PTH anabolic actions. Western blotting and real-time PCR were performed to detect Bcl2 expression in calvarial osteoblasts in response to PTH ex vivo.

Results: There were reduced numbers of osteoclasts in Bcl2(-/-) mice, with a resultant increase in bone mass. Bcl2(-/-) bone marrow-derived osteoclasts ex vivo were significantly larger in size and short-lived compared with wildtype, suggesting a pro-apoptotic nature of Bcl2(-/-) osteoclasts. In contrast, osteoblasts were entirely normal in their proliferation, differentiation, and mineralization. Intermittent administration of PTH increased bone mass similarly in Bcl2(+/+) and Bcl2(-/-) mice. Finally, Western blotting and real-time PCR showed that Bcl2 levels were not induced in response to PTH in calvarial osteoblasts.

Conclusions: Bcl2 is critical in osteoclasts but not osteoblasts. Osteoclast suppression is at least in part responsible for increased bone mass of Bcl2(-/-) mice, and Bcl2 is dispensable in PTH anabolic actions during bone growth.

Citing Articles

Casticin Inhibits Osteoclastogenesis via NF-κB/BCL-2 Signaling Pathway.

Huang A, Gu Z, Jin J, Nie T J Microbiol Biotechnol. 2025; 35:e2409009.

PMID: 39947684 PMC: 11876008. DOI: 10.4014/jmb.2409.09009.

Unveiling Genetic Potential for Equine Meat Production: A Bioinformatics Approach.

Simon M, Kaic A, Potocnik K Animals (Basel). 2024; 14(16).

PMID: 39199974 PMC: 11350750. DOI: 10.3390/ani14162441.

Deficiency in Osteoblasts Reduces the Trabecular Bone Due to Enhanced Osteoclastogenesis Likely through Osteoblast Apoptosis.

Moriishi T, Kawai Y, Fukuyama R, Matsuo Y, He Y, Akiyama H Int J Mol Sci. 2023; 24(24).

PMID: 38139148 PMC: 10743571. DOI: 10.3390/ijms242417319.

Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth.

Velentza L, Wickstrom M, Kogner P, Ohlsson C, Zaman F, Savendahl L Sci Rep. 2023; 13(1):8054.

PMID: 37198212 PMC: 10192431. DOI: 10.1038/s41598-023-34965-4.

Anabolic actions of parathyroid hormone in a hypophosphatasia mouse model.

Koh A, Kyung Nam H, Michalski M, Do J, McCauley L, Hatch N Osteoporos Int. 2022; 33(11):2423-2433.

PMID: 35871207 PMC: 9568459. DOI: 10.1007/s00198-022-06496-7.

References

Berry J, Ealba E, Pettway G, Datta N, Swanson E, Somerman M . JunB as a downstream mediator of PTHrP actions in cementoblasts. J Bone Miner Res. 2006; 21(2):246-57. DOI: 10.1359/JBMR.051024. View

Garcia I, Martinou I, Tsujimoto Y, Martinou J . Prevention of programmed cell death of sympathetic neurons by the bcl-2 proto-oncogene. Science. 1992; 258(5080):302-4. DOI: 10.1126/science.1411528. View

Chen H, Demiralp B, Schneider A, Koh A, Silve C, Wang C . Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J Biol Chem. 2002; 277(22):19374-81. DOI: 10.1074/jbc.M108913200. View

Lukert B, Raisz L . Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990; 112(5):352-64. DOI: 10.7326/0003-4819-112-5-352. View

Vaux D, Cory S, Adams J . Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988; 335(6189):440-2. DOI: 10.1038/335440a0. View

Davies J, Evans B, Jenney M, Gregory J . In vitro effects of chemotherapeutic agents on human osteoblast-like cells. Calcif Tissue Int. 2002; 70(5):408-15. DOI: 10.1007/s002230020039. View

Lynch M, Capparelli C, Stein J, Stein G, Lian J . Apoptosis during bone-like tissue development in vitro. J Cell Biochem. 1998; 68(1):31-49. View

Boot-Handford R, Michaelidis T, Hillarby M, Zambelli A, Denton J, Hoyland J . The bcl-2 knockout mouse exhibits marked changes in osteoblast phenotype and collagen deposition in bone as well as a mild growth plate phenotype. Int J Exp Pathol. 1999; 79(5):329-35. PMC: 3220196. DOI: 10.1046/j.1365-2613.1998.790411.x. View

Bellido T, Ali A, Plotkin L, Fu Q, Gubrij I, Roberson P . Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003; 278(50):50259-72. DOI: 10.1074/jbc.M307444200. View

10.

Calvi L, Adams G, Weibrecht K, Weber J, Olson D, Knight M . Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003; 425(6960):841-6. DOI: 10.1038/nature02040. View

11.

Zhu J, Garrett R, Jung Y, Zhang Y, Kim N, Wang J . Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood. 2007; 109(9):3706-12. DOI: 10.1182/blood-2006-08-041384. View

12.

MALLUCHE H, Faugere M . Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int. 1990; 38(2):193-211. DOI: 10.1038/ki.1990.187. View

13.

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

14.

Servet-Delprat C, Arnaud S, Jurdic P, Nataf S, Grasset M, Soulas C . Flt3+ macrophage precursors commit sequentially to osteoclasts, dendritic cells and microglia. BMC Immunol. 2002; 3:15. PMC: 134601. DOI: 10.1186/1471-2172-3-15. View

15.

Stanislaus D, Yang X, Liang J, Wolfe J, Cain R, Onyia J . In vivo regulation of apoptosis in metaphyseal trabecular bone of young rats by synthetic human parathyroid hormone (1-34) fragment. Bone. 2000; 27(2):209-18. DOI: 10.1016/s8756-3282(00)00309-4. View

16.

Gohel A, McCarthy M, Gronowicz G . Estrogen prevents glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro. Endocrinology. 1999; 140(11):5339-47. DOI: 10.1210/endo.140.11.7135. View

17.

Taichman R, Reilly M, Emerson S . Human osteoblasts support human hematopoietic progenitor cells in vitro bone marrow cultures. Blood. 1996; 87(2):518-24. View

18.

Pettway G, Schneider A, Koh A, Widjaja E, Morris M, Meganck J . Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone. Bone. 2005; 36(6):959-70. DOI: 10.1016/j.bone.2005.02.015. View

19.

Marchetti M, Di Marco B, Cifone G, Migliorati G, Riccardi C . Dexamethasone-induced apoptosis of thymocytes: role of glucocorticoid receptor-associated Src kinase and caspase-8 activation. Blood. 2002; 101(2):585-93. DOI: 10.1182/blood-2002-06-1779. View

20.

Pagel C, de Niese M, Abraham L, Chinni C, Song S, Pike R . Inhibition of osteoblast apoptosis by thrombin. Bone. 2003; 33(4):733-43. DOI: 10.1016/s8756-3282(03)00209-6. View